EL7.AI
StocksUpdated•Originally published 14 April 2026•Updated 16 April 2026•
1 min read

Gilead Sciences Faces Protests Over HIV Drug Pricing Policies

Key Facts

1The AIDS Healthcare Foundation (AHF) blasted Gilead Sciences over what it termed extortionate pricing for HIV/AIDS medications.
2AHF organized protests in San Francisco to highlight the company's drug pricing policies.

Tensions surrounding Gilead Sciences (GILD) have intensified as protests spread to Florida following claims by the AIDS Healthcare Foundation (AHF) regarding high treatment costs. The AHF alleges that the cost of Biktarvy exceeds $4,000 per month, leading to its removal from Florida's AIDS Drug Assistance Program (ADAP) formulary. Advocates warn that this move leaves thousands of patients facing uncertain access to essential healthcare. In response, Gilead asserted that it provides significant discounts and has committed to a price freeze through 2026. Investors are closely monitoring how these expanding demonstrations and program exclusions might impact the company's reputation. The ongoing friction between corporate pricing and public health access continues to pose a regulatory risk for the pharmaceutical giant.